Cerus Corporation - Common Stock (CERS)

A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability.

REDeS trial met efficacy endpoints; ISC revenue surged 44% year over year.

Cerus (NASDAQ:CERS) reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS study of pathogen-reduced red blood cells. Product revenue totaled $57.7 million for the quarter

Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas. Product revenue totaled $57.4 million for the quarter ended June

Cerus (CERS) Q1 2026 Earnings Transcript

Cerus (CERS) Q4 2025 Earnings Call Transcript

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.